A number of methods will be used for cell therapies, especially in cell expansion. Autologous and allogeneic therapies have different needs.

Digitalization and automation are the major drivers to reduce cycle times and costs, and increase the overall work in progress.

Researchers say new yeast biosynthetic platform provides "vast opportunities" to produce structural variants of QS-21 and identify new adjuvant leads.

We catch up with Mammoth Biosciences CSO Lucas Harrington after his ASGCT presentation. Harrington lays out his company's big plans in developing a range of therapeutic options using miniature Cas ...

The Crick Institute plans to leverage Broken String’s DNA break-mapping platform to develop novel applications for ALS treatments.

Pfizer has paused enrollment in a Phase III trial assessing its Duchenne muscular dystrophy (DMD) gene therapy candidate ...

A recently-developed technique for measuring the mass of single molecules in solution has the potential to help companies ...

Solvias says its new center complements its biologics and CGT sites in Europe and expands its testing capabilities in the ...

In one of the opening workshops at ASGCT 2024, topics around delivery methods for gene therapies and approaches to expand the gene editing toolbox dominated the discussion. The quality of the ...

Discoveries about PARP1 biology generate questions that could aid in development of new PARP1-targeting strategies.